Treating Pulmonary Embolism with Laguna Thrombectomy System (TRUST)
a study on Pulmonary Embolism
Summary
- Eligibility
- for people ages 18-85 (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedcompletion around
Description
Summary
This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.
Keywords
Pulmonary Embolism, Laguna Thrombectomy System, Embolism
Eligibility
You can join if…
Open to people ages 18-85
- ≥ 18 years of age; < 85 years old
- RV/LV ratio > 0.9 as determined by CTA
- Systolic blood pressure > 90 mmHg
- Heart rate ≤ 120
- Patient is deemed eligible for procedure by the interventional investigator
- CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
- PE Symptom duration ≤ 14 days
You CAN'T join if...
- Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments
- Life expectancy of < 90 days in the opinion of investigator at the time of enrollment
- Subject pregnant or breast feeding
- Current participation in another drug or medical device treatment study
- In active chemotherapy or radiation treatment for a malignancy during the course of the study
- Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days
- Presence of recently placed (<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium
- History of prior PE within the past 90 days
- FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90%
- Hematocrit: < 28%
- Platelets: < 100,000/microliter
- Serum Creatinine: > 2 mg/dL
- International Normalized Ratio (INR): > 3
- Major Trauma Injury Severity Score (ISS): > 15
- Cardiovascular or pulmonary surgery within the last 7 days
- Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation
- History of known severe or chronic pulmonary arterial hypertension
- History or chronic left heart disease with left ventricular ejection fraction < 30%
- History of underlying lung disease that is oxygen dependent
- History of chest irradiation
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
- Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants
- Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
- Known presence of clot in transit within right atrium or ventricle
Locations
- University of California Irvine
accepting new patients
Irvine California 92697 United States - Mission Hospital Regional Medical Center
accepting new patients
Mission Viejo California 92691 United States - St. Joseph Hospital of Orange
accepting new patients
Orange California 92868 United States - Memorial Care Long Beach Medical Center
accepting new patients
Long Beach California 90806 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Innova Vascular, Inc.
- ID
- NCT06041594
- Study Type
- Interventional
- Participants
- Expecting 107 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.